Outcome of radical retropubic prostatectomy at the Lagos State University Teaching Hospital

Stephen Odunayo Ikuerowo1,2, Alaba Fredrick Doherty2, Muftau Jimoh Bioku3, Abimbola Ayodeji Abolarinwa3, Adekunle Azeez Adebayo4, Steves Olaide Oyeleke4, Olufunmilade Akinfolarin Omisanjo1,2

ABSTRACT

Background: Prostate cancer is the most commonly diagnosed cancer in men in Nigeria and most cases present when the disease is already in an advanced stage. Radical prostatectomy for early prostate cancer is therefore not a commonly performed operation by urologists in Nigeria. We have had training and significant experience in radical retropubic prostatectomy. We, therefore, report the outcome of our initial experience. Materials and Methods: We review the record of men with early prostate cancer who had radical retropubic prostatectomy in our institution from 2007 to 2015. Results: There were 34 men who had radical retropubic prostatectomy in the 8-year period of review. The youngest and oldest patients were aged 50 and 71 years, respectively. The mean age was 64.2 years. All the patients were diagnosed following 12-core ultrasound-guided transrectal prostate biopsy for elevated serum prostate specific antigen (PSA). The mean serum PSA was 15.3 (range 8.5–100.3) ng/ml. The disease was pT1, pT2, and pT3 in 6, 20, and 8 patients respectively. General anesthesia was employed in 28 (82.4%) patients and combined epidural and subarachnoid block anesthesia for 6 (17.6%) patients. The total duration of operation was 128–252 min (mean = 160 min). No blood transfusion was given in 5 (14.7%) patients while each of the remaining 29 (85.3%) patients had 2–5 units of blood intra- or post-operatively. There was no perioperative mortality. Complications include operation-induced erectile dysfunction in 12 (35.3%), major urinary incontinence in 1 (2.9%), lymphocele in 2 (5.9%), and reoperation due to anastomotic leak and right ureteric injury in 1 (2.9%). After a median follow-up of 42 months, disease recurrence has occurred in 3 (8.8%) patients 1 (2.9%) of whom has died of diabetic renal failure. Conclusion: Radical prostatectomy can be safely performed in men with early prostate cancer in Nigeria and should be offered to suitable patients.

Key words: Nigeria, outcome, prostate cancer, radical prostatectomy

INTRODUCTION

Prostate cancer is the most commonly diagnosed cancer in men worldwide1 and in Nigeria where most cases present when the disease is already in the advanced stage.2–4 However, with the improving awareness and prostate specific antigen (PSA) screening for the disease in Lagos, Nigeria, early cases of prostate cancer requiring radical curative operation are being seen.4,5 Radical prostatectomy is the gold standard for early prostate cancer6 and has been shown to reduce progression to metastasis and death from the disease in randomized controlled trials.7 However, open radical prostatectomy is technically one of the most difficult operations in the field of urology and most urologists in Nigeria and West Africa do not have the expertise and experience for this operation.8,9 The training
of the authors included a significant experience in radical retropubic prostatectomy. We, therefore, report our initial experience on radical retropubic prostatectomy, which to the best of our knowledge is the first in Nigeria.

MATERIALS AND METHODS

We carried out a review of a prospectively collected data on all patients who underwent radical retropubic prostatectomy at our institution from October 2007 to September 2015. Data obtained included the patient’s biodata, preoperative history (including preoperative erectile status) and clinical examination, imaging findings (computed tomography (CT) scan, magnetic resonance imaging (MRI), and isotope bone scan as available), type of anesthesia, length of operation, blood transfusion, postoperative complications, and the tumor characteristics. The data were analyzed using IBM-SPSS Statistics 21 (SPSS, Inc., Chicago, IL, USA).

RESULTS

The clinical and pathological features are summarized in Table 1. There were 34 men who had radical retropubic prostatectomy during the period. The ages were 50–71 years and a mean age of 64.2 years. The mean body weight was 79 (range 68–115) kg and the mean body mass index (BMI) was 28.5 (range 23.5–34.8) kg. Five (14.7%), 24 (70.6%), 5 (14.7%) men were classified as normal, overweight, and obese BMI categories respectively. All patients were asymptomatic for prostate cancer, and the diagnosis was made after 12-core systematic transrectal ultrasound-guided prostate biopsy for elevated serum PSA. Only 10 (29.4%) patients had preoperative lower urinary tract symptoms due to bladder outlet obstruction. Preoperative erectile dysfunction was present in 13 (38.2%) patients. The serum total PSA was 8.5–100.3 (mean 15.3) ng/mL. Two (5.9%) patients had serum PSA >20 ng/mL (50.2 and 100.5 ng/mL). Imaging for the further staging of cancer included CT scan of the pelvis or MRI of the prostate in 32 (94.1%) and isotope bone scan in 30 (88.2%) patients. The patients were staged as cT1 and cT2 disease in 8 (23.5%) and 26 (76.5%) patients respectively and N0 and N1 in 32 (94.1%) and 2 (5.9%) patients, respectively. None of the patients had any evidence of distant metastatic disease. All patients had adenocarcinoma of the prostate. Reported radical prostatectomy specimen Gleason scores were ≤6, 7 and 8–10 in 3 (8.8%), 22 (64.7%), and 9 (26.5%) patients, respectively. The postoperative pathological staging were pT1c, pT2, pT3 in 6 (17.7%), 20 (58.8%), and 8 (23.5%) respectively and pN0, pN1 in 32 and 2, respectively.

Unilateral nerve sparing radical retropubic prostatectomy was performed in 9 (26.5%), bilateral nerve sparing radical retropubic prostatectomy in 18 (52.9%), and no nerve sparing in 7 (20.6%) patients. General anesthesia was employed in 28 (82.4%) patients and combined epidural and subarachnoid block anesthesia for 6 (17.6%) patients. The latter was particularly useful in achieving postoperative analgesia. Bilateral pelvic (obturators) lymphadenectomy was routinely performed for all the patients before proceeding to prostatectomy. The total duration of operation was 128–252 min (mean = 160 min). No blood transfusion was given in 5 (14.7%) patients while each of the remaining 29 (85.3%) patients had 2–5 units of blood intra- or post-operatively. There was no perioperative mortality recorded. Urethral catheter was removed for 31 (91.2%) patients at 21st day postoperation after the cystogram showed no leakage. Three (8.8%) patients had catheterization for up to 6 weeks postoperation.

Postoperative complications recorded were summarized in Table 2. Anastomotic leak and ureteric injury occurred each in 1 (4.2%) patient, and the patients had repair of the anastomotic leak and ureteric reimplantation. Two patients developed lymphocele, one of which resolved spontaneously by 10th postoperative day and the other had percutaneous drainage of the lymphocele and instillation of sclerosant. In addition, 1 (2.9%) had bladder neck stenosis that responded well to bouginage.

Urinary incontinence was recorded in 5 (20.8%) patients (1 continuous and 4 stress incontinence) persisting beyond

| Parameter | n (%) |
|-----------|-------|
| Age (years) |       |
| 50-60 | 8 (23.5) |
| 60-70 | 20 (58.8) |
| ≥70 | 6 (17.7) |
| Mean (median) | 64.2 (65) |
| BMI (kg/m²) |       |
| Normal weight | 5 (8.8) |
| Overweight | 24 (70.6) |
| Obese | 5 (8.8) |
| Mean BMI | 28.5 |
| Serum PSA (ng/ml) |       |
| >20 | 9 (26.5) |
| 11-20 | 23 (67.6) |
| >20 | 2 (5.9) |
| Mean (median) | 15.3 (12.8) |
| Tumour stage |       |
| pT1c | 6 (17.7) |
| pT2 | 20 (59.4) |
| pT3 | 8 (23.5) |
| Nerve-sparing surgery |       |
| None | 7 (20.6) |
| Unilateral | 9 (26.5) |
| Bilateral | 18 (52.9) |
| Blood transfusion |       |
| Yes | 29 (85.3) |
| No | 5 (14.7) |

BMI – Body mass index; PSA – Prostate specific antigen
We, therefore, expect a reduction as we gather more cases. However, no prostate cancer-specific mortality has been recorded.

The follow-up period ranged from 3 to 96 (median = 42) months. Biochemical recurrence with elevated serum PSA has been recorded in 3 patients at 24, 38 and 62 postoperative months, respectively. The first patient had who had preoperative PSA of 15.5 ng/mL and pathological stage of pT2bN0M0 was found to have PSA rise up to 8 ng/mL at 24 postoperative months and was commenced on goserelin. The second patient had postoperative radiotherapy and goserelin. This patient died 6 years postradical prostatectomy from complications of diabetes. However, no prostate cancer-specific mortality has been recorded.

**DISCUSSION**

Radical prostatectomy is performed for clinically localized prostate cancer, usually discovered through PSA screening. Although screening for prostate cancer is currently controversial, it is recommended that annual PSA and digital rectal examination screening should be carried out among high-risk individuals such as black men with life expectancy ≥10 years. Although there is no formal screening program for prostate cancer in Nigeria, there is an annual public awareness campaign in Lagos state. This has resulted in identifying some early cases of prostate cancer suitable for radical prostatectomy, and they form a significant part of our series of radical prostatectomy.

Prostate cancer is known to have poorer clinical and pathological features among men of African descent, but access to curative surgery for localized disease in West African is very limited. There has been no report of radical retropubic prostatectomy, one of the most major operations performed in urology, anywhere in Nigeria. This is largely because most cases of prostate cancer present in the advanced stage. Those cases that present early are rarely offered radical prostatectomy due to limited expertise and experience in our environment. In this study, only 34 cases were reported over an 8-year period, and this underscores the low prevalence of radical prostatectomy in our environment.

The mean age among our patients is comparable to other reports from populations of African descent. However, many of our patients are men who were asymptomatic but discovered from routine screening, unlike these previous studies. The mean serum PSA of 15.4 ng/mL was quite similar but slightly lower than what was reported from similar study in Ghana (16.1 ng/mL) and much higher than that from West Indies (10.1 ng/mL). Good cancer control has been achieved following radical prostatectomy among our patients. Only in three patients have disease recurrence been recorded and no patient has died directly from prostate cancer. The only death recorded is from complication of diabetes.

The operation time has progressively been reducing as we perform more cases. Obese patients tend to have a more difficult surgery and therefore higher operation time. Our mean operation time of 160 min is comparable to what is obtained in already established centers, but our transfusion rate of 85.3% is rather high. This may be due to the initial experience of both the surgical and anesthetic teams. A previous study reported a transfusion rate drop from 88.8% in 1998 to 9.1% in 2002 after defining a transfusion trigger. We, therefore, expect a reduction in transfusion rate as we gain more experience. Although majority of the patients were operated under general anesthesia, the use of combined subarachnoid and epidural block was particularly beneficial for postoperative analgesia and therefore would be recommended for radical prostatectomy. The complications we recorded are comparable to what has been reported elsewhere, but we expect a reduction as we gather more cases.

**CONCLUSION**

Radical prostatectomy is feasible in our setting with good oncological outcomes and few complications. The operation should be offered to suitable patients with localized prostate cancer in our environment.

**Financial support and sponsorship**

Nil.
Ikuerowo, et al.: Radical prostatectomy is safe and has good oncological outcome in Lagos, Nigeria

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505-27.
2. Osegbe DN. Prostate cancer in Nigerians: Facts and nonfacts. J Urol 1997;157:1340-3.
3. Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. J Nati Med Assoc 1999;91:159-64.
4. Ikuerowo SO, Omisanjo OA, Bioku MJ, Ajala MO, Mordi VP, Esho JO. Prevalence and characteristics of prostate cancer among participants of a community-based screening in Nigeria using serum prostate specific antigen and digital rectal examination. Pan Afr Med J 2013;15:129.
5. Ogundele SO, Ikuerowo SO. A survey of the awareness of prostate cancer and its screening among men attending the outpatient clinics of a tertiary health center in Lagos, Nigeria. Niger J Surg 2015;21:115-8.
6. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate. J Urol 2000;163:1802-7.
7. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932-42.
8. Ruenes A Jr., Gueye SM. Teaching radical prostatectomy in Sub-Saharan Africa. Can J Urol 2008;15:3886-9.
9. Kyei MY, Mensah EJ, Gepi-Attee S, Kwami D, Ampadu K, Asante E, et al. Outcomes after radical prostatectomy in ghanaians: A surgeon’s early experience. ISRN Urol 2013;2013:832496.
10. Heyns CF, Fisher M, Lecuona A, van der Merwe A. Prostate cancer among different racial groups in the Western Cape: Presenting features and management. S Afr Med J 2011;101:267-70.
11. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444-9.
12. Morrison BF, Aiken WD, Mayhew R. Current state of prostate cancer treatment in Jamaica. Ecancermedicalscience 2014;8:456.
13. Morrison BF, Coard K, Strachan G, Miller R, Aiken W, Mayhew R. Radical prostatectomy outcomes at the University Hospital of the West Indies: 2000-2007. West Indian Med J 2011;60:68-72.
14. Paul R, Schmid R, Busch R, van Randenborgh H, Alschibaja M, Schöler S, et al. Influence of blood transfusions during radical retropubic prostatectomy on disease outcome. Urology 2006;67:137-41.
15. Shirley SE, Escoffery CT, Sargeant LA, Tulloch T. Clinicopathological features of prostate cancer in Jamaican men. BJU Int 2002;89:390-5.
16. Ritch CR, Morrison BF, Hruby G, Coard KC, Mayhew R, Aiken W, et al. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: An international comparison. BJU Int 2013;111 (4 Pt B):E186-90.